Stockscreener 앱 받기
1.35
0.00%
0.00
전일 마감가:
$1.35
열려 있는:
$1.35
하루 거래량:
72,142
Relative Volume:
0.72
시가총액:
$22.51M
수익:
$3.20M
순이익/손실:
$-10.90M
주가수익비율:
-2.0036
EPS:
-0.6738
순현금흐름:
$-7.92M
1주 성능:
-4.26%
1개월 성능:
-4.93%
6개월 성능:
+6.30%
1년 성능:
-11.18%
1일 변동 폭
$1.33
$1.3501
1주일 범위
$1.33
$1.45
52주 변동 폭
$0.8099
$4.07
마커 테라퓨틱스 Stock (MRKR) Company Profile
명칭
Marker Therapeutics Inc
전화
(713) 400-6400
주소
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.35 | 22.51M | 3.20M | -10.90M | -7.92M | -0.6738 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
마커 테라퓨틱스 Stock (MRKR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 개시 | Canaccord Genuity | Buy |
| 2021-03-25 | 개시 | Piper Sandler | Overweight |
| 2021-03-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-03-01 | 개시 | Janney | Buy |
| 2018-12-03 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
마커 테라퓨틱스 주식(MRKR)의 최신 뉴스
Marker Therapeutics (MRKR) Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Inches HigherEPS Growth Report - newsline.com
MRKR Q1 2026 Earnings: Narrower-than-expected loss highlights cost management amid pipeline progressGuidance vs Actual - newsline.com
Marker Therapeutics (MRKR) Holds Steady Above Support as Biotech Sector Shows Mixed SignalsHigh Dividend Factor - newsline.com
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
MRKR Q1 2026 Earnings: Smaller-than-Expected Loss Surprises PositivelyProfit Growth Outlook - newsline.com
Marker Therapeutics (MRKR) Dips 2.55%, Challenging Support Near $1.45Value Stock Ideas - newsline.com
Pancreatic Cancer Clinical Trial Pipeline Gains Momentum: 170+ - openPR.com
Mrkr Q1 2026 Earnings: EPS Beats Estimates as Company Advances PipelineFinal Results - The Legal Advocate
Marker Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Biotech Advances PipelinePre-Announcement Alert - The Legal Advocate
Marker Therapeutics (MRKR) Faces Pressure: Stock Slips 2.1% to $1.4Undervalued Stocks - newsline.com
Marker Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline ProgressesMargin Compression Risk - Newser
Marker Therapeutics Inc. (MRKR) Q1 2026 Earnings: EPS Beat Expectations Amid Development Stage OperationsRevenue Estimate Trend - Newser
Marker Therapeutics Q1 2026 Earnings: Loss Narrows as Clinical Progress ContinuesPost-Earnings Drift - Newser
Marker Therapeutics (MRKR) upgraded to buy: What does it mean for the stock? - MSN
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Marker Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Marker Therapeutics (MRKR) narrows Q1 2026 loss but warns on going concern - Stock Titan
Marker Therapeutics, Inc. Q1 2026: Net loss $(3.18M), Diluted EPS $(0.16) — 10-Q Summary - TradingView
MRKR: Net loss improved to $3.2M in Q1 2026, with cash funding expected through Q1 2027 - TradingView
Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Marker Therapeutics (MRKR) Fell -0.82% — Is a Recovery Ahead? 2026-05-15Community Pattern Alerts - Newser
Marker Therapeutics (MRKR) Q4 2025 Earnings: $-0.09 EPS Surges Past $-0.20 EstimatesNew Analyst Coverage - Newser
OnCusp Therapeutics names seasoned finance exec Kim CFO - ROI-NJ
OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer - The Manila Times
TradingKey - tradingkey.com
Marker Therapeutics MRKR Q4 2025 loss narrows unexpectedly, beating estimates by 55%; shares tick higher.Crowd Entry Points - Newser
Number of shareholders of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
MSN Money - MSN
Marker Therapeutics, Inc. (MRKR) reports Q4 loss, tops revenue estimates - MSN
Marker Therapeutics Shareholders Approve Governance and Capital Changes - The Globe and Mail
Marker Therapeutics (NASDAQ: MRKR) holders back share increase but reject voting change - Stock Titan
High Growth Tech Stocks in the US Market to Watch - simplywall.st
Pancreatic Cancer Pipeline Enters a New Era of Precision - openPR.com
Is Marker Therapeutics (MRKR) stock moving unpredictably (Ticks Down) 2026-04-24Safe Entry Stocks - newser.com
High Growth Tech Stocks To Watch In US April 2026 - simplywall.st
Is Marker Therapeutics (MRKR) stock worth buying today | Q4 2025: EPS Exceeds ExpectationsFinancial Data - Cổng thông tin điện tử tỉnh Lào Cai
Marker Therapeutics (MRKR) price target decreased by 12.83% to 8.02 - MSN
Stock List: Research Stocks from Around the World - GuruFocus
Ideas Watch: What are Marker Therapeutics Incs growth levers2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-04-06 22:29:12 - baoquankhu1.vn
Can Marker Therapeutics (MRKR) Stock Rebound in 2026 | Price at $1.44, Up 9.09%CTA Positioning - newsline.com
Total debt per share of Marker Therapeutics, Inc. – FWB:GX1 - TradingView
EBITDA per share of Marker Therapeutics, Inc. – FWB:GX1 - TradingView
Marker Therapeutics, Inc. (MRKR) stock price, news, quote and history - Yahoo Finance UK
EPS Watch: What is the long term forecast for Marker Therapeutics Inc stock2026 Volatility Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Is Marker Therapeutics (MRKR) Stock Leading the Market | Price at $1.77, Up 1.14%Protective Put - The Legal Advocate
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
MRKR SEC FilingsMarker Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Sell: Can Marker Therapeutics Inc deliver consistent dividends2026 Fed Impact & Free Reliable Trade Execution Plans - baoquankhu1.vn
마커 테라퓨틱스 (MRKR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):